In canines, does the oral administration of carprofen, when compared to meloxicam, result in fewer gastrointestinal side effects?
Clinical bottom line
Category of research question
The number and type of study designs reviewed
Three prospective randomised controlled trials were critically reviewed
Strength of evidence
Treatment with carprofen or meloxicam results in no significant difference in gastric lesion scoring, increased intestinal mucosal permeability or diminished small bowel absorptive capacity
There is insufficient evidence supporting preferential administration of carprofen or meloxicam to reduce gastrointestinal side effects
The application of evidence into practice should take into account multiple factors, not limited to: individual clinical expertise, patient’s circumstances and owners’ values, country, location or clinic where you work, the individual case in front of you, the availability of therapies and resources.
Knowledge Summaries are a resource to help reinforce or inform decision-making. They do not override the responsibility or judgement of the practitioner to do what is best for the animal in their care
Banerjee, A., Chitnis, U. B., Jadhav, S. L., Bhawalkar, J. S., & Chaudhury, S. (2009). Hypothesis testing, type I and type II errors. Industrial Psychiatry Journal, 18(2), 127–131. DOI: https://doi.org/10.4103/0972-6748.62274
Bruno, A., Tacconelli, S. & Patrignani, P. (2014). Variability in the response to non-steroidal anti-inflammatory drugs: Mechanisms and perspectives. Basic and Clinical Pharmacology and Toxicology, 114(1). DOI: http://dx.doi.org/10.1111/bcpt.12117
Craven, M., Chandler, M. L., Steiner, J. M., Farhadi, A., Welsh, E., Pratschke, K., Shaw, D. J., & Williams, D. A. (2007). Acute effects of carprofen and meloxicam on canine gastrointestinal permeability and mucosal absorptive capacity. Journal of Veterinary Internal Medicine, 21(5), 917–23. DOI: http://dx.doi.org/10.1111/j.1939-1676.2007.tb03043.x
Forsyth, S. F., Guilford, W. G., Haslett, S. J., & Godfrey, J. (1998). Endoscopy of the gastroduodenal mucosa after carprofen, meloxicam and ketoprofen administration in dogs. Journal of Small Animal Practice, 39(9), 421–424. DOI: http://dx.doi.org/10.1111/j.1748-5827.1998.tb03748.x
Fox, S.M. & Johnston, S.A. (1997). Use of carprofen for the treatment of pain and inflammation in dogs. Journal of the American Veterinary Medical Association, 210, 1493–8.
Innes, J., Clayton, J. & Lascelles, D. (2010). Long-term NSAID use for canine OA: is it more effective? Proceedings, 3rd World Veterinary Orthopaedic Congress, ESVOT-VOS, 15th ESVOT Congress, Bologna, Italy, 15–18 September, 341–342.
Luna, S. P., Basílio, A. C., Steagall, P. V., Machado, L. P., Moutinho, F. Q., Takahira, R. K., & Brandão, C. V. (2007). Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs. American Journal of Veterinary Research, 68(3), 258–264. DOI: http://dx.doi.org/10.2460/ajvr.68.3.258
Monteiro-Steagall, B.P., Steagall, P.V.M. & Lascelles, B.D.X. (2013). Systematic review of nonsteroidal anti-inflammatory drug-induced adverse effects in dogs. Journal of Veterinary Internal Medicine, 27(5), 1011–1019. DOI: http://dx.doi.org/10.1111/jvim.12127
Pigott, J., Cobb, M. & O’Rourke, D. (2015). A comprehensive review of adverse events associated with non-steroidal anti-inflammatory drug treatments in dogs in the UK. BSAVA Congress 2015: Scientific Proceedings, Birmingham, UK, 9–12 April 2015. DOI: http://dx.doi.org/10.22233/9781910443521.70.12
Rice, J.E. & Ihle, S.L. (1994). Effects of diet on fecal occult blood testing in healthy dogs. Canadian Journal of Veterinary Research = Revue canadienne de recherche vétérinaire, 58(2), 134–137.
Valencia Sánchez, F., Gutiérrez Pérez, E. & Pérez Carral, V. (2008). Calcinosis cutis en iguana. Argos: Informativo Veterinario, 58–60.
Copyright (c) 2020 Aaron Harold Andrew Fletcher
This work is licensed under a Creative Commons Attribution 4.0 International License.
Veterinary Evidence uses the Creative Commons copyright Creative Commons Attribution 4.0 International License. That means users are free to copy and redistribute the material in any medium or format. Remix, transform, and build upon the material for any purpose, even commercially - with the appropriate citation.